| Company Name: |
Syncozymes (Shanghai) Co.,Ltd.
|
| Tel: |
021-68187180-819 13681683526 |
| Email: |
lchen@syncozymes.com |
| Products Intro: |
Product Name:CMPF, 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid
CAS:86879-39-2
Purity:95% Package:100g;1kg; 25kg; 100kg or More
|
| Company Name: |
Yichang Zhongyitai Trading Co., Ltd.
|
| Tel: |
0717-6449896 13886658719 |
| Email: |
root@zhongyitai.com |
| Products Intro: |
Product Name:3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid
CAS:86879-39-2
Purity:>98% Package:5mg
|
|
| Product Name: | CMPF | | Synonyms: | CMPF;3-carboxy-4-methyl-5-propyl-2-furanpropionic acid;3-[(3-Carboxy-4-methyl-5-propylfuran)-2-yl]propionic acid;3-Carboxy-4-methyl-5-propylfuran 2-propanoic acid;Furanic acid;Propylfuranoic acid;CMPF, 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid;2-(2-carboxyethyl)-4-methyl-5-propylfuran-3-carboxylic acid | | CAS: | 86879-39-2 | | MF: | C12H16O5 | | MW: | 240.25 | | EINECS: | | | Product Categories: | | | Mol File: | 86879-39-2.mol |  |
| Melting point | >174°C (Subl.) | | Boiling point | 404.0±45.0 °C(Predicted) | | density | 1.236±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | Chloroform (Very Slightly), DMSO (Slightly), Ethyl Acetate (Slightly), Methanol | | form | Solid | | pka | 4.38±0.10(Predicted) | | color | White to Pale Beige |
| Uses | CMPF is a drug-binding inhibitor which is also a constituent of urine. CMPF can inhibit specific T4 binding in serum by increasing the free concentration of direct competitors. | | Definition | ChEBI: A furoic acid that is furan-3-carboxylic acid substituted by a methyl group at position 4, a propyl group at position 5 and a 2-carboxyethyl group at position 2. It is a potent uremic toxin that has been found to accumulate in human serum of patients with
hronic kidney diseases. | | General Description | 3-Carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF), a major metabolite of furan fatty acids, is a uremic toxin (UT), excreted into the urine via organic,anion transporters under physiological conditions. It is mostly reported to be accumulated in chronic kidney disease (CKD) patients. Monitoring of CMPF may be important to predict organic anion transporting polypeptide (OATP)1B activity in CKD patients as studies have implicated a decreased trend in (OATP)1B activity in patients with this uremic toxin. It is also found to be in increased concentrations, for patients who progress from prediabetes to type 2 diabetes, patients with renal failure, polyunsaturated fatty acids with high-temperature cooking and subjects who consume fish or fish oil. |
| | CMPF Preparation Products And Raw materials |
|